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1607-551X/Copyright ª 2015, KaohsiuAbstract The aim of this study was to investigate whether anticoagulant and antiaggregant
agents have protective effects against oxidative damage induced by peripheral ischemia
ereperfusion (I/R). Groups were created as follows: control group, I/R group (sham group),
I/R plus acetylsalicylic acid (Group I), I/Rþclopidogrel (Group II), I/Rþrivaroxaban (Group
III), I/Rþbemiparin sodium (Group IV), and I/Rþenoxaparin sodium (Group V). In Groups I,
II, III, IV, and V, drugs were administered daily for 1 week before I/R creation. Peripheral I/
R was induced in the I/R groups by clamping the right femoral artery. The rats were sacrificed
1 hour after reperfusion. Nitrogen oxide levels, malondialdehyde (MDA) levels, paraoxonase-1
(PON1) activity, and prolidase activity were evaluated in both cardiac and renal tissues. There
was no significant difference in nitrogen oxide levels between the groups. However, cardiac
and renal MDA were significantly higher and PON1 activity was markedly lower in the I/R groups
compared with the control group (p< 0.05). Although elevated prolidase activity was detected
in both the cardiac and renal tissue of the I/R groups, only the sham group and Group V had
significantly higher renal prolidase activity (p< 0.05). Group V had significantly higher cardiac
MDA, PON1, prolidase levels, and renal prolidase activity compared with the sham group
(p< 0.05). Significant improvement in renal MDA levels was only observed in Group III, and
marked improvement was observed in the cardiac MDA levels of Group II when compared witheclare no conflicts of interests.
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116 S. Demirtas et al.the sham group (p< 0.05). Thromboprophylactic agents appear to provide partial or prominent
protection against I/R injury.
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Thrombosis can locally obstruct distal flow and cause distal
ischemia or disrupt distant organ perfusion via emboli [1].
Therefore, thrombosis prophylaxis regimens for prevention
of ischemic complications in high-risk populations are
frequently investigated [2]. Thrombosis and embolic events
can occur despite sufficient management and even when
appropriate antithrombotic therapy is administered [3].
Treatment for both acute embolic and thrombotic occlusion
focuses on reperfusion of the ischemic limb. Reducing the
adverse outcomes of the ischemic injury is also a main
target of treatment [1]. Furthermore, the duration of
ischemic exposure is an important determinant of tissue
recovery and of the undesired effects of reperfusion [4,5].
Therefore, receiving prophylaxis prior to thrombosis-
induced ischemia is important.
Antiaggregant and anticoagulant agents can be used for
thromboprophylaxis [6]. Previous investigations of anti-
aggregant agents have claimed that these agents modulate
vascular smooth muscle and induce apoptosis, as well as
inhibit platelet adhesion and aggregation [7]. Previous re-
ports have also identified antioxidant effects of anti-
aggregant drugs [8]. Similarly, antithrombotic agents have
cellular effects, on growth factor regulation and cell
adhesion, in addition to preventing new thrombosis for-
mation [9,10]. Previous studies have also mentioned
possible antioxidant features of antithrombotic agents
[10,11].
The purpose of the present study was to investigate and
compare the possible cardiac and renal protective effects
of thromboprophylactic agents against ische-
miaereperfusion (I/R) injury in an experimental peripheral
I/R model.
Materials and methods
All animal procedures were approved by the Animal
Research Committee of Dicle University and were per-
formed in accordance with the Animal Welfare Act and the
Guide for the Care and Use of Laboratory Animals pre-
pared by the ethics committee. The principal investigator,
animal laboratory staff, and the primate handling staff
were present for all procedures. Study design and protocol
was created according to our previous experimental
modeling [12].
Animals
Fifty-six male SpragueeDawley rats (aged 8e12 weeks)
weighing 230  30 g (mean  standard deviation) were usedfor this study. The rats were obtained from the Laboratory
Animal Production Unit of the university. All rats were
maintained in standard humidity (50  5%) and temperature
(22  2C) controlled cages with a 12-hour light/dark cycle
for 1 week prior to the start of the study.
Study protocol
The rats were randomly divided into seven equal groups. All
operations were performed simultaneously on sham and
study groups for sample standardization. All rats were
anesthetized with ketamine (Ketalar; Pfizer, Ta¨by,
Sweden) at a dose of 130 mg/kg and xylazine (Rompun;
Bayer, Gothenburg, Sweden) at a dose of 20 mg/kg via an
intraperitoneal line. Maintenance of anesthesia was pro-
vided with ketamine hydrochloride (50 mg/kg).
Experimental ischemia/reperfusion injury model
preparation
The right femoral artery was clamped for 6 hours and then
the clamp was removed to create reperfusion. Two millili-
ters of blood samples were obtained from inferior vena
cava at the 1st hour of reperfusion. The rats were sacrificed
1 hour after reperfusion, and cardiac tissue samples and
left kidneys were obtained.
Eight of the rats were placed in the control group at the
beginning of the study, and 2 mL of blood samples from
inferior vena cava, cardiac tissue samples, and left kidneys
were obtained for determining the baseline nitrogen oxide
(NOx) levels, malondialdehyde (MDA) levels, and
paraoxonase-1 (PON1) and prolidase activity in blood,
renal, and cardiac tissue without any intervention. The
remaining rats were separated for experimental I/R injury
induction.
The six peripheral I/R injury groups of eight animals
each were as follows:
Sham group: I/R only.
Group I (n Z 8): Acetylsalicylic acid (ASA, Coraspin;
Bayer, Leverkusen, Germany) was administered orally via
gavage at a dose of 30 mg/kg/day beginning 1 week prior to
the start of study. I/R was induced after 1 week of drug
administration.
Group II (n Z 8): Clopidogrel bisulfate (Planor; Koc¸ak
Farma, Tekirdag, Turkey) was administered orally via
gavage at a dose of 1 mg/kg/day beginning 1 week prior to
the start of the study. I/R was induced after 1 week of drug
administration.
Group III (n Z 8): Rivaroxaban (Xarelto; Bayer Schering
Pharma AG, Wuppertal, Germany) was administered orally
via gavage at a dose of 3 mg/kg/day beginning 1 week prior
to the start of the study. I/R was induced after 1 week of
drug administration.
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0.2 mL; Laboratorios Farmaceuticos Rovi SA, Spain) was
administered intraperitoneally at a dose of 250 U/kg/day
beginning 1 week prior to the start of the study. I/R was
induced after 1 week of drug administration.
Group V (nZ 8): Enoxaparin sodium (Oksapar 2000 ANTI-
XA IU/0.2 mL; Koc¸ak Farma, Tekirdag, Turkey) was admin-
istered intraperitoneally at a dose of 250 U/kg/day begin-
ning 1 week prior to the start of the study. I/R was induced
after 1 week of drug administration.Laboratory analysis
Blood samples (2 mL) were obtained from vena cava for
evaluating NOx, MDA, PON1, and prolidase levels in plasma.
Samples were centrifuged at 4042 g (4000 RPM at 22.6 cm)
at þ4C for 10 minutes to obtain plasma. Thereafter,
plasmas were transferred into Eppendorf tubes. After ani-
mals were sacrificed, hearts and left kidneys from all
groups were dissected at 4C and quickly frozen in liquid
nitrogen. Tissue was homogenized in 9 mL of 0.25M sucrose
and 10mM EDTA (pH 7.4) using a Teflon homogenizer to
obtain a 10% suspension, and centrifuged at 3800  g for 30
minutes. Tissue extracts and blood samples were stored at
70C until further analysis.
NOx measurement
Nitrogen oxide (NOx) levels, an available measure of
platelet-derived nitric oxide,were detected using the Gri-
ess reagent method. The method is based on a modified
cadmium reaction as described in Yavuz et al [4]. A cali-
bration curve was provided by adding the Griess reagent
into 0mM, 20mM, 40mM, 60mM, 80mM, and 100 mM solu-
tions of sodium nitrite and reading the optical density (OD)
at 545 nm on a spectrophotometer (Bio-tek Instruments
Inc., Winooski, VT, USA). NO concentrations were calcu-
lated as mmol/l for blood samples and mM/g protein for
tissue extracts.
MDA measurement
Changes in tissue lipid peroxidation levels were determined
by measuring malondialdehyde (MDA) levels, determined by
the quantity of thiobarbituric acid reactive products.
Advanced glycation end products and MDA levels were
determined according to the method described by Ohkawa
et al [13]. MDA values were expressed as mM for blood
samples and mM/g protein for tissue extracts.
Prolidase measurement
Prolidase levels were determined spectrophotometrically
based on measurement of proline, a prolidase product,
using the method described by Myara et al. [14]. Proline
levels (expressed as U/L for blood samples and U/g protein
for tissue extracts) were detected by measuring the
absorbance at 515 nm.
PON1 measurement
PON1 levels were determined spectrophotometrically using
the modified Eckerson method. The hydrolysis rate of par-
aoxon (0.0-diethyl-0-p-nitrophenylphosphate; Sigma
Chemical Co., London, UK) was determined by measuringliberated p-nitrophenol at 405 nm and 37C [15]. PON1
activity was expressed as U/L for blood samples and U/g
protein for tissue extracts.
Statistical analysis
All statistical analyses were performed using SPSS software
version 15.0 (SPSS Inc., Chicago, IL, USA). All results are
expressed as mean  standard deviation. Continuous vari-
ables were compared using one-way analysis of variance
(ANOVA). The control group, sham group, and other study
groups were compared using the Dunnett test for posthoc
analysis. A p-value  0.05 was considered statistically
significant.
Results
The blood NOx, MDA, PON1, and prolidase levels were
12.1  3.2mM, 21.4  19.3mM, 103.5  89.3 U/L,
102.2  111.1 U/g in control group, respectively. Changes
in NOx and PON1 levels in sham and study groups were
found to be insignificant. However, the MDA levels were
significantly increased in the sham group (155.6  88.5mM)
when compared with baseline levels in control group
(p > 0.05). Moreover, the decrement of serum MDA levels in
drug groups (Group I, II, III, IV, V) was statistically signifi-
cant compared with the sham group (p< 0.001). Addition-
ally, the prolidase levels were significantly increased in the
sham group (1748.2  1148.8 U/g) when compared with the
control group (p< 0.05). Prolidase levels were significantly
decreased in Group II (313.4  241.7 U/g), Group III
(513.2  488.0 U/g) and Group IV (491.1  376.3 U/g)
compared with the sham group. The serum values of
oxidative markers are compared between groups in Table 1.
The baseline cardiac levels of biochemical oxidative
markers in the control group were as follows: NOx,
11.05  0.12mM/g protein; MDA, 84.12  8.98mM/g protein;
PON1, 71.83  8.91 U/g protein; prolidase,
265.62  37.19 U/g protein. The values for renal tissue
were as follows: NOx, 12.04  3.99mM/g protein; MDA,
7.52  2.21mM/g protein; PON1, 101.35  7.12 U/g protein;
and prolidase, 14.40  1.58 U/g protein.
NOx values for the sham group were not significantly
different: 9.09  4.94mM/g protein in cardiac tissue and
13.56  3.82mM/g protein in renal tissue (p > 0.05). The I/R
groups treated with thromboprophylactic regimens had
insignificantly higher values compared with the sham group
(ANOVA, F Z 1.98, p Z 0.11). Cardiac NOx levels were as
follows: 25.68  15.76mM/g protein in the group treated
with acetylsalicylic acid (Group I), 9.40  4.36mM/g protein
in the group treated with clopidogrel bisulfate (Group II),
27.84  16.70mM/g protein in the group treated with
rivaroxaban (Group III), 14.29  15.86mM/g protein in the
group treated with bemiparin sodium (Group IV), and
12.61  5.80mM/g protein in the group treated with enox-
aparin sodium (Group V). Conversely, the treated groups
had insignificantly lower renal NOx levels: 11.62  1.99mM/
g protein, 11.99  1.14mM/g protein, 8.49  1.92mM/g
protein, 11.33  0.70mM/g protein, and 12.59  1.53mM/g
protein for Groups I, II, III, IV, and V, respectively,
compared with the sham group (ANOVA, F Z 1.63,
Table 1 The evaluation and comparison of oxidative markers in blood samples and posthoc analysis between groups.
n Z 8 for each group NOx (mM) MDA (mM) Prolidase (U/g) PON1 (U/L) Posthoc analysis
Control group 12.1  3.2 21.4  19.3 102.2  111.1 103.5  89.3 p *
# U
Sham group 9.2  1.7 155.6  88.5 1748.2  1148.8 117.2  99.9 Sham vs. control < 0.001 0.001
Acetylsalicylic
acid (Group I)
14.3  5.9 54.5  48.1 712.0  512.2 83.6  49.2 Sham vs. Group I 0.006 0.069
Clopidogrel (Group II) 12.6  4.4 42.6  35.5 313.4  241.7 97.0  79.1 Sham vs. Group II 0.000 0.012
Rivaroxaban (Group III) 19.2  9.5 31.6  33.5 513.2  488.0 109.6  69.7 Sham vs. Group III 0.002 0.036
Bemiparin (Group IV) 16.8  4.6 39.5  27.2 491.1  376.3 77.9  57.5 Sham vs. Group IV 0.001 0.028
Enoxaparin (Group V) 18.4  7.1 45.2  30.9 701.5  617.4 86.8  72.6 Sham vs. Group V 0.005 0.062
p (One-way ANOVA) 0.612 <0.001 0.042 0.089 #: p for MDA
U : p for prolidase
*p < 0.05 is significant
MDA Z malondialdehyde; NOx Z nitrogen oxide; PON1 Z paraoxonase 1.
118 S. Demirtas et al.p Z 0.18). The NOx levels of the different groups are
compared in Fig. 1.
MDA levels were significantly higher in the sham group
(243.56  9.60mM/g protein in cardiac tissue and
19.76  4.99mM/g protein in renal tissue) compared with
the controls (p< 0.001). In contrast, groups treated with
thromboprophylactic agents had lower cardiac MDA levels:
170.69  29.85mM/g protein, 151.67  45.01mM/g protein,
162.25  26.89mM/g, protein 172.95  30.89mM/g protein,
and 149.65  33.42mM/g protein for Groups I, II, III, IV, and
V, respectively (ANOVA, F Z 10.44, p< 0.001). Renal MDA
levels were as follows: 17.72  3.09mM/g protein,
11.69  2.25mM/g protein, 14.66  3.52mM/g protein,
7.42  1.28mM/g protein, and 13.73  0.90mM/g protein for
the five treatment groups, respectively (ANOVA, FZ 33.84,
p< 0.001). The MDA values of the different groups are
summarized in Fig. 2.
I/R groups had significantly lower PON1 levels in cardiac
(ANOVA, F Z 76.71, p< 0.001) and renal tissue (ANOVA,
F Z 316.19, p< 0.001) compared with the control group.
Lower PON1 levels were observed in the sham group
(23.46  2.39 U/g protein in cardiac tissue and
13.59  4.15 U/g protein in renal tissue) compared withFigure 1. (A) Nitrogen oxide levels in cardiac tissue extracts. (B
were obtained from the control group; Sham: I/R only; Group I: I
treated with clopidogrel; Group III: I/R group treated with rivaroxa
group treated with enoxaparin. p< 0.05 was considered statisticalthe control group (p< 0.001). The treatment groups had
slightly higher values compared with the sham group
(p > 0.05). For the treatment groups, cardiac PON1 levels
were as follows: 33.30  3.22 U/g protein, 28.09  2.62 U/
g protein, 39.42  0.41 U/g protein, 37.61  6.21 U/g
protein, and 31.20  3.01 U/g protein. Renal PON1 levels
were detected as 16.35  2.23 U/g protein,
16.61  1.62 U/g protein, 16.68  3.45 U/g protein,
16.57  2.68 U/g protein, and 15.52  1.59 U/g protein for
Groups I, II, III, IV, and V, respectively. PON1 levels are
compared in Fig. 3.
The I/R study groups had markedly different prolidase
values from the controls in both cardiac and renal tissue
(ANOVA, F Z 5.22, p Z 0.002 and F Z 146.47, p< 0.001,
respectively). Prolidase levels were significantly higher in
the sham group samples, 5149.54  3386.47 U/g protein
(p Z 0.001) in cardiac tissue and 95.62  3.96 U/g protein
(pZ 0.006) in renal tissue. The drug treatment groups had
a range of lower prolidase values compared with the sham
group. Prolidase values were as follows in Groups I, II, III,
IV, and V, respectively: 804.87  205.54 U/g protein,
1155.97  1.51 U/g protein, 1020.27  910.46 U/g protein,
1159.53  1389.40 U/g protein, and 349.54  3386.47 U/g) Nitrogen oxide levels in renal tissue extracts. Baseline values
/R group treated with acetylsalicylic acid; Group II: I/R group
ban; Group IV: I/R group treated with bemiparin; Group V: I/R
ly significant.
Figure 2. (A) Malondialdehyde levels in cardiac tissue extracts. (B) Malondialdehyde levels in renal tissue extracts. Baseline
values were obtained from the control group; Sham: I/R only (p Z sham vs. baseline); Group I: I/R group treated with acetylsa-
licylic acid (pZ sham vs. Group I); Group II: I/R group treated with clopidogrel (pZ sham vs. Group II); Group III: I/R group treated
with rivaroxaban (pZ sham vs. Group III); Group IV: I/R group treated with bemiparin (pZ sham vs. group IV); Group V: I/R group
treated with enoxaparin (p Z sham vs. Group V).
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73.58  4.20 U/g protein, 58.79  3.74 U/g protein,
70.42  4.88 U/g protein, and 20.56  5.84 U/g protein in
renal tissue. Prolidase levels are compared between groups
in Fig. 4.Discussion
This study demonstrated that I/R induces oxidative stress in
cardiac and renal tissues. The sham group had higher car-
diac and renal prolidase and MDA levels and lower cardiac
and renal PON1 levels compared with the baseline levels of
the control group. No significant differences in NOx values
were observed. However, all of the I/R drug treatment
groups except the rivaroxaban group had slightly higher
NOx levels. Differences between the sham group and the
drug groups were insignificant. Cardiac and renal MDAFigure 3. (A) PON1 levels in cardiac tissue extracts; (B) PON1 lev
the control group; Sham: I/R only (pZ sham vs. baseline); Group I:
I); Group II: I/R group treated with clopidogrel (pZ sham vs. Group
Group III); Group IV: I/R group treated with bemiparin (p Z sham
(p Z sham vs. Group V).levels of the drug treatment groups were lower than those
of the sham group (p< 0.05). After thromboprophylaxis, all
of the drug groups had lower MDA levels compared with the
sham group. However, the decrease was statistically insig-
nificant (p > 0.05).
As a result of I/R, the highest cardiac and renal prolidase
values occurred in the sham group. The drug treatment
groups had decreased cardiac and renal prolidase levels
compared with the sham group. Furthermore, only cardiac
prolidase levels differed significantly between the sham
group and the drug treatment groups (all except the
enoxaparin sodium group). Renal prolidase levels were
markedly lower, almost at baseline values, for the group
treated with enoxaparin sodium (p Z 0.001). To our
knowledge, this is the first study to compare the cardiac
and renal protective effects of antiaggregants and antico-
agulants (including the new oral anticoagulant rivaroxaban)
in an experimental I/R model.els in renal tissue extracts. Baseline values were obtained from
I/R group treated with acetylsalicylic acid (pZ sham vs. Group
II); Group III: I/R group treated with rivaroxaban (pZ sham vs.
vs. Group IV); Group V: I/R group treated with enoxaparin
Figure 4. (A) Prolidase levels in cardiac tissue extracts. (B) Prolidase levels in renal tissue extracts. Baseline values were ob-
tained from the control group; Sham: I/R only (p Z sham vs. baseline); Group I: I/R group treated with acetylsalicylic acid
(p Z sham vs. Group I); Group II: I/R group treated with clopidogrel (p Z sham vs. Group II); Group III: I/R group treated with
rivaroxaban (p Z sham vs. Group III); Group IV: I/R group treated with bemiparin (p Z sham vs. Group IV); Group V: I/R group
treated with enoxaparin (p Z sham vs. Group V).
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plays a role in many molecular, cellular, and physiological
events, such as the metabolism of proteins, lipids, and
nucleic acids [4]. In particular, NOx is reported to be a
critical mediator, and thus, an important signaling mole-
cule for cardiovascular health [4,16]. Oxidative stress,
inflammation, endothelial dysfunction, and apoptotic
events have been associated with a lack of nitric oxide
activity [4,17]. ASA, which inhibits cyclooxygenase, was
previously found to inhibit the inducible form of nitric oxide
and its products of oxidation in infracted heart muscle in
situ by Kimura et al [18]. Conversely, de la Cruz et al re-
ported that ASA stimulates NOx production from neutro-
phils and elevates plasma nitrite/nitrate levels [19]. In our
study, administration of ASA caused insignificant elevation
in cardiac NOx levels and a minimal decrease in renal NOx
levels (p > 0.05). Clopidogrel, a platelet ADP receptor
antagonist, was found to increase endothelial nitric oxide
bioavailability and demonstrated vasoprotective effects in
patients with symptomatic coronary artery disease [20].
Kanko et al reported reducing the effects of clopidogrel on
plasma, liver, and lung NO in an experimental I/R model
[21]. We detected insignificant changes in cardiac and renal
NOx levels in the group treated with clopidogrel. Higher
cardiac NO levels were reported in rats treated with topical
low molecular weight heparins (LMWHs) by He et al [22].
Lakshmi et al reported that LMWHs improve wound healing
by reducing nitric oxide synthetase levels [23]. In the cur-
rent study, we did not find any significant changes in groups
treated with either oral or injectable factor Xa inhibitor
(rivaroxaban or enoxaparin sodium and bemiparin sodium,
respectively).
MDA is a product of lipid peroxidation in processes
associated with oxidative stress [24]. Ulubas‚ et al reported
that MDA levels were reduced with ASA treatment in
cisplatin-induced oxidative stress [25]. Kanko et al studied
the protective effects of clopidogrel on oxidant damage in
a rat ischemia reperfusion model, and they reported
increased MDA levels in rats treated clopidogrel [21]. Con-
trastingly, MDA levels decreased in diabetic patientstreated with clopidogrel in a study by Taher and Nassir [26].
Additionally, clopidogrel treatment was found to reduce
oxidative stress in patients with type 2 diabetes [26]. Deepa
and Varalakshmi studied the possible protective effects of
LMWHs on cardiac and renal oxidative changes induced by
experimental atherogenesis, and they reported that LMWHs
reduced lipid peroxidation and demonstrated protective
effects against oxidative damage [27]. Similar to previous
reports, we found that both cardiac and renal MDA levels
were reduced in I/R-induced rats treated with thrombo-
prophylactic agents. In particular, renal MDA levels were
reduced to baseline values in I/R-induced rats treated with
bemiparin sodium (p< 0.01).
PON1 is a liver enzyme that hydrolyzes various types of
substrates, such as arylesters, phosphate esters, and lac-
tones [28]. Decreased PON1 levels were reported during
oxidative stress by Cebeci et al [29]. Jaichander et al sug-
gested that the antiatherosclerotic properties of ASA might
be mediated by induction of PON1 [28]. Tselepis et al
claimed that PON1 enzyme activity is inversely related to
clopidogrel efficacy as a determinant of antiplatelet ac-
tivity [30]. Topsakal et al reported that enoxaparin sodium
leads to alterations in PON1 activity during acute oxidative
stress in an experimental model of spinal cord injury [31].
However, in our study, significant differences in cardiac and
renal PON1 activity were not detected in I/R groups who
received thromboprophylactic treatment compared with
the sham group.
Prolidase is an essential cytosolic enzyme that has been
demonstrated to play an important role in collagen meta-
bolism [32]. Higher prolidase levels during oxidative stress
have been previously reported [32]. Miltyk et al claimed
that nonsteroidal anti-inflammatory drugs inhibit prolidase
activity in cultured human skin fibroblasts [33]. In addition,
ASA was determined to be an inhibitor of collagen synthesis
by inhibiting prolidase activity [34]. In particular, renal
tissue is the most prolidase-rich structure of the human
body [35]. Thus, we investigated cardiac and renal tissue
levels of prolidase in an experimental I/R model with and
without thromboprophylactic treatment. Both cardiac and
Thrombosis prophylaxis and I/R injury 121renal prolidase levels were significantly higher in the I/R
group that did not receive thromboprophylactic treatment
(sham group) compared with the baseline values (control
group). I/R groups that received thromboprophylactic
treatment had dramatically lower cardiac prolidase values
compared with the sham group. The most distinct differ-
ence in cardiac prolidase levels was observed in the group
treated with enoxaparin sodium, in which cardiac values
were almost baseline values. Furthermore, only the enox-
aparin sodium group had statistically significantly lower
prolidase levels.
In conclusion, thromboprophylaxis with antiaggregant
and antithrombotic agents is important for preventing
ischemic disorders. Furthermore, thrombotic and embolic
complications can occur even when thromboprophylactic
treatment is administered. Nevertheless, thromboprophy-
laxis with antiaggregant or anticoagulant agents seems to
have protective efficacy against both renal and cardiac
oxidative damage in I/R conditions.
The major limitation of this study was the animal model.
The limitation concerns the creation of isolated I/R without
thrombotic tendency. Thrombosis may lead to different
results in different study groups with thrombotic tendency.
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